Neuroimaging MAO-B in Medication Free TR-MDD Using Novel Tracer (DETB)

Center for Addiction and Mental Health (CAMH)

Status: Completed

Conditions: Major Depressive Disorder

Treatments: Other: phenelzine treatment

Study type: Interventional

Funder types: Other

Identifiers

NCT02153281

DETB-071-13

Details and patient eligibility

About

The purpose of this study is to determine if monoamine oxidase B (MAO-B) total distribution volume (VT), after phenelzine treatment and if so to what extent.

Full description

Subjects will receive a PET and MRI scan before and after treatment with phenelzine.

Enrollment: 8 patients

Sex: All

Ages: 18 to 80 years old

Volunteers: No Healthy Volunteers

Inclusion criteria

• 18-80 years of age
• good physical health
• Diagnostic and Statistical Manual of Mental Disorders (DSM-IV) diagnosis of current major depressive episode (MDE)
• DSM-IV diagnosis of major depressive disorder (MDD) verified by SCID for DSM-IV and a psychiatric consultation
• greater than 17 on the 17 item HDRS (Hamilton Depression Rating Scale).
• history of non-response to several different antidepressant classes

Exclusion criteria

• herbal, drug or medication use (that affect CNS function)
• suicide attempts
• drug or medication use within eight weeks (+5 half lives of medication)
• history of substance abuse or any neurotoxin use
• history of psychotic symptoms
• history of central nervous system (CNS) medical illness
• current substance abuse
• test positive on pregnancy test (for women)

Trial design

Primary purpose: Treatment

Allocation: N/A

Interventional model: Single Group Assignment

Masking: None (Open label)

---

8 participants in 1 patient group

Phenelzine treatment

Experimental group

Description:

Subjects will undergo a PET and MRI scan before and after the treatment.

Treatment:

Other: phenelzine treatment